Kurse + Charts + RealtimeNews + AnalysenFundamentalUnternehmenzugeh. WertpapiereAktion
Kurs + ChartChart (groß)NewsBilanz/GuVDividende/HVZertifikateDepot/Watchlist
Times + SalesChart-AnalyseAnalysenSchätzungenTermineOptionsscheinemyHome
BörsenplätzeChartvergleichKurszieleVergleichProfilKnock-OutsSenden/Drucken
OrderbuchRealtime StuttgartFundamentalanalyseRatingInsidertradesFondsInvestmentreport
HistorischRealtime PushmyNewsAusblickim ForumAnleihen
Kaufen
Verkaufen

13.06.2012 16:00

Senden

UBS Declares Monthly Coupon Payment on RWXL ETN

UBS zu myNews hinzufügen Was ist das?


UBS Investment Bank announces coupon payment for the ETRACS Monthly Pay 2xLeveraged Dow Jones International Real Estate ETN (Ticker: RWXL), which is linked to The Dow Jones Global ex-U.S. Select Real Estate Securities Index (the "Index”).

The table below summarizes the relevant coupon information for RWXL:

                             
NYSE Arca Ticker   Name   Coupon Valuation Date   Ex-Date   Record Date   Payment Date   Coupon Amount per Note   Current Yield (annualized)*
RWXL   ETRACS Monthly Pay 2xLeveraged Dow Jones International Real Estate ETN   05/30/2012   06/08/2012   06/12/2012   06/20/2012   $0.3051   17.12%

* "Current Yield” equals the current Coupon Amount annualized and divided by the closing price of the ETN on May 30, 2012 or, if the closing price is not available on May 30, 2012, the previous available closing price, and rounded to two decimal places for ease of analysis. You are not guaranteed any coupon or distribution amount under the ETNs.

Note: RWXL pays a variable monthly coupon linked to 2 times the cash distributions, if any, on the Index constituents, less any withholding taxes. Variations in the amount of monthly distributions will lead to large variations in the Current Yield as calculated above. As such, the Current Yield is not indicative of future coupon payments, if any, on RWXL.

About ETRACS

For further information about ETRACS ETNs, go to http://www.etracs.com.

Exchange Traded Access Securities ETNs ("ETRACS ETNs”) are exchange-traded notes, an innovative class of investment products offering access to markets and strategies that may not be readily available to investors, and offer unique diversification opportunities in a number of different sectors. ETRACS ETNs may offer:

  • Access to asset classes with historically low correlations to more traditional asset classes
  • Convenience of an exchange-traded security
  • Transparent exposure to a published index

ETRACS ETNs are senior unsecured notes issued by UBS AG, are traded on NYSE Arca, and can be bought and sold through a broker or financial advisor. An investment in ETRACS ETNs is subject to a number of risks, including the risk of loss of some or all of the investor’s principal, and is subject to the creditworthiness of UBS AG. You are not guaranteed any coupon or distribution amount under the ETNs. We urge you to read the more detailed explanation of risks described under "Risk Factors” in the product supplement and pricing supplement for the ETRACS ETN.

The contents of any website referred to in this communication are not part of, or incorporated by reference in, this communication. UBS has filed a registration statement (including a prospectus, as supplemented by a product supplement and pricing supplement for the offering of the ETRACS ETN with the Securities and Exchange Commission (the "SEC”) for the offering to which this communication relates. Before you invest, you should read these documents and any other documents that UBS has filed with the SEC for more complete information about UBS and the offering to which this communication relates. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, you can request the prospectus and the applicable prospectus supplement by calling toll-free (+1.877.387.2275). Past performance is not necessarily indicative of future results.

This material is issued by UBS AG or an affiliate thereof ("UBS"). Products and services mentioned in this publication may not be available for residents of certain jurisdictions. Past performance is not necessarily indicative of future results. Please consult the restrictions relating to the product or service in question for further information. Activities with respect to US securities are conducted through UBS Securities LLC, a US broker/dealer. Member of SIPC (http://www.sipc.org/).

ETRACS ETNs are sold only in conjunction with the relevant offering materials. UBS has filed a registration statement (including a prospectus, as supplemented by a prospectus supplement for the offering of the ETRACS ETNs) with the Securities and Exchange Commission (the "SEC") for the offerings to which this communication relates. Before you invest, you should read these documents and any other documents that UBS has filed with the SEC for more complete information about UBS and the offerings to which this communication relates. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, you can request the prospectus and the applicable prospectus supplement by calling toll-free (+1-877-387 2275). In the US, securities underwriting, trading and brokerage activities and M&A advisor activities are provided by UBS Securities LLC, a registered broker/dealer that is a wholly owned subsidiary of UBS AG, a member of the New York Stock Exchange and other principal exchanges, and a member of SIPC. UBS Financial Services Inc. is a registered broker/dealer and affiliate of UBS Securities LLC.

UBS specifically prohibits the redistribution or reproduction of this material in whole or in part without the prior written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. © UBS 2012. The key symbol, UBS and ETRACS are among the registered and unregistered trademarks of UBS. The "Dow Jones Global ex-U.S. Select Real Estate Securities Index SM” is a product of Dow Jones Indexes, the marketing name and a licensed trademark of CME Group Index Services LLC ("CME"), and has been licensed for use. "Dow Jones®", "Dow Jones Global ex-U.S. Select Real Estate Securities Index SM” and "Dow Jones Indexes" are service marks of Dow Jones Trademark Holdings, LLC ("Dow Jones") have been licensed to CME and have been sublicensed for use for certain purposes by UBS AG. All rights reserved.

The ETRACS Monthly Pay 2xLeveraged Dow Jones International Real Estate ETN is not sponsored, endorsed, sold or promoted by Dow Jones, CME or their respective affiliates. Dow Jones, CME and their respective affiliates make no representation or warranty, express or implied, to the owners of the ETRACS Monthly Pay 2xLeveraged Dow Jones International Real Estate ETN or any member of the public regarding the advisability of trading in the Product(s). Dow Jones', CME’s and their respective affiliates’ only relationship to the Licensee is the licensing of certain trademarks and trade names of Dow Jones and of the Dow Jones Global ex-U.S. Select Real Estate Securities Index which is determined, composed and calculated by CME without regard to UBS AG or the ETRACS Monthly Pay 2xLeveraged Dow Jones International Real Estate ETN. Dow Jones and CME have no obligation to take the needs of UBS AG or the owners of the ETRACS Monthly Pay 2xLeveraged Dow Jones International Real Estate ETN into consideration in determining, composing or calculating "Dow Jones Global ex-U.S. Select Real Estate Securities Index SM. Dow Jones, CME and their respective affiliates are not responsible for and have not participated in the determination of the timing of, prices at, or quantities of the ETRACS Monthly Pay 2xLeveraged Dow Jones International Real Estate ETN to be sold or in the determination or calculation of the equation by which the ETRACS Monthly Pay 2xLeveraged Dow Jones International Real Estate ETN are to be converted into cash. Dow Jones, CME and their respective affiliates have no obligation or liability in connection with the administration, marketing or trading of the ETRACS Monthly Pay 2xLeveraged Dow Jones International Real Estate ETN. Notwithstanding the foregoing, CME Group Inc. and its affiliates may independently issue and/or sponsor financial products unrelated to the ETRACS Monthly Pay 2xLeveraged Dow Jones International Real Estate ETN currently being issued by UBS AG, but which may be similar to and competitive with the ETRACS Monthly Pay 2xLeveraged Dow Jones International Real Estate ETN. In addition, CME Group Inc. and its affiliates may trade financial products which are linked to the performance of the Dow Jones Global ex-U.S. Select Real Estate Securities IndexSM. It is possible that this trading activity will affect the value of the Dow Jones Global ex-U.S. Select Real Estate Securities Index SM and ETRACS Monthly Pay 2xLeveraged Dow Jones International Real Estate ETN.

DOW JONES, CME AND THEIR RESPECTIVE AFFILIATES DO NOT GUARANTEE THE ACCURACY AND/OR THE COMPLETENESS OF THE DOW JONES GLOBAL EX-U.S. SELECT REAL ESTATE SECURITIES INDEX OR ANY DATA INCLUDED THEREIN AND DOW JONES, CME AND THEIR RESPECTIVE AFFILIATES SHALL HAVE NO LIABILITY FOR ANY ERRORS, OMISSIONS, OR INTERRUPTIONS THEREIN. DOW JONES, CME AND THEIR RESPECTIVE AFFILIATES MAKE NO WARRANTY, EXPRESS OR IMPLIED, AS TO RESULTS TO BE OBTAINED BY UBS AG, OWNERS OF THE ETRACS MONTHLY PAY 2XLEVERAGED DOW JONES INTERNATIONAL REAL ESTATE ETN, OR ANY OTHER PERSON OR ENTITY FROM THE USE OF THE DOW JONES GLOBAL EX-U.S. SELECT REAL ESTATE SECURITIES INDEX OR ANY DATA INCLUDED THEREIN. DOW JONES, CME AND THEIR RESPECTIVE AFFILIATES MAKE NO EXPRESS OR IMPLIED WARRANTIES, AND EXPRESSLY DISCLAIM ALL WARRANTIES, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE WITH RESPECT TO THE DOW JONES GLOBAL EX-U.S. SELECT REAL ESTATE SECURITIES INDEX OR ANY DATA INCLUDED THEREIN. WITHOUT LIMITING ANY OF THE FOREGOING, IN NO EVENT SHALL DOW JONES, CME OR THEIR RESPECTIVE AFFILIATES HAVE ANY LIABILITY FOR ANY LOST PROFITS OR INDIRECT, PUNITIVE, SPECIAL OR CONSEQUENTIAL DAMAGES OR LOSSES, EVEN IF NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES. THERE ARE NO THIRD PARTY BENEFICIARIES OF ANY AGREEMENTS OR ARRANGEMENTS BETWEEN CME AND UBS AG, OTHER THAN THE LICENSORS OF CME.

Notes to Editors

UBS draws on its 150-year heritage to serve private, institutional and corporate clients worldwide, as well as retail clients in Switzerland. We combine our wealth management, investment banking and asset management businesses with our Swiss operations to deliver superior financial solutions.

UBS is present in all major financial centers worldwide. It has offices in over 50 countries, with about 37% of its employees working in the Americas, 37% in Switzerland, 16% in the rest of Europe and 10% in Asia Pacific. UBS employs about 65,000 people around the world. Its shares are listed on the SIX Swiss Exchange and the New York Stock Exchange (NYSE).

www.ubs.com/media

Follow us on Twitter: www.ubs.com/twitteramericas

Kommentare zu diesem Artikel

Geben Sie jetzt einen Kommentar zu diesem Artikel ab.
Kommentar hinzufügen
  • Relevant
    1
  • Alle
    1
  • vom Unternehmen
  • Peer Group
  • Sprache:
  • Alle
  • DE
  • EN
  • Sortieren:
  • Datum
  • meistgelesen
Hebelprodukte
Risikobereitschaft auf Rekordhoch
Die Risikofreude von Discountzertifikate-Anlegern ist im März auf ein Jahresrekordhoch gestiegen. » mehr
17.04.14
UBS Names U.S. Head for Complex Equities Group (EN, The Wall Street Journal Deutschland)
17.04.14
Taiwan Semi Rising: Q1 Beats; UBS Ups to Buy, $140 Target (EN, The Wall Street Journal Deutschland)
17.04.14
UBS Burgdorf zügelt in einen Neubau (Finenews.ch)
17.04.14
Entlassungswelle: UBS-Kader bangen um ihre Jobs (20min.ch)
17.04.14
UBS ist führend in Sachen Transparenz (Finenews.ch)
17.04.14
UBS: Von «exklusiv» zu «einer von vielen» (Handelszeitung)
16.04.14
Gefährliche Liebschaft einer UBS-Bankerin (Finenews.ch)
16.04.14
UBS vertraut in Asien den Frauen (Finenews.ch)
Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen
Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen
vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden
Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu UBS AG (N)

mehr
  • Alle
  • Buy
  • Hold
  • Sell
15.04.14UBS buyGoldman Sachs Group Inc.
11.04.14UBS buyDeutsche Bank AG
31.03.14UBS overweightJP Morgan Chase & Co.
20.03.14UBS OutperformMacquarie Research
10.03.14UBS overweightMorgan Stanley
15.04.14UBS buyGoldman Sachs Group Inc.
11.04.14UBS buyDeutsche Bank AG
31.03.14UBS overweightJP Morgan Chase & Co.
20.03.14UBS OutperformMacquarie Research
10.03.14UBS overweightMorgan Stanley
05.02.14UBS haltenIndependent Research GmbH
05.02.14UBS haltenExane-BNP Paribas SA
30.01.14UBS haltenCredit Suisse Group
04.12.13UBS haltenIndependent Research GmbH
18.11.13UBS haltenCredit Suisse Group
26.08.13UBS verkaufenNorddeutsche Landesbank (Nord/LB)
21.08.13UBS verkaufenBankhaus Lampe KG
05.02.13UBS verkaufenKepler Equities, Inc.
28.12.12UBS verkaufenNorddeutsche Landesbank (Nord/LB)
30.10.12UBS underperformCheuvreux SA
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für UBS AG (N) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen
Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"

AKTIEN IN DIESEM ARTIKEL

UBS AG (N)14,63
1,98%
UBS Jahreschart

ANZEIGE

Private Krankenversicherung Tarifvergleich

Anzeige

ANZEIGE

Die 5 beliebtesten Top-Rankings






Die Zahl der Beschwerden von Privatversicherten über ihre Krankenkasse ist 2013 leicht gesunken. Wie Zufrieden sind Sie mit Ihrer Krankenkasse?
Ich gehöre zu denen die sich beim Ombudsmann der privaten Krankenversicherung (PKV) beschwert haben.
Ich war im letzten Jahr unzufrieden, habe mich aber nicht beschwert.
Ich hatte keine Probleme mit meiner Versicherung
Abstimmen